Abstract 1731P
Background
BRAF gene mutation, especially V600E, was frequently mutated in cancer. Vemurafenib and dabrafenib have already been approved for the treatment of melanoma, NSCLC and colorectal carcinoma. However, the landscape of BRAF mutation in Chinese solid tumor was rarely descripted.
Methods
4,124 normal-paired samples from patients with solid tumors were analyzed using hybridization capture-based next generation sequencing, and alterations including single base substitution, short and long insertion/deletions, copy number variations, gene fusions and rearrangements.
Results
BRAF was altered in 3.1% (129 of 4,124) of all solid tumors. The frequency of BRAF V600E variations was assessed in multiple cancer types, including lung cancer (20/2283), colorectal cancer (15/455), hepatocellular cancer (2/156), and other cancer types. The BRAF non-V600 mutations (K601E/N, D594G, G469A/V, N581S, N597R, G466V/A, D594N/E, G464R, F357C, V157I, V130M, T599dup, T241M) were also assessed in multiple cancer types. Furthermore, we found that the BRAF functional mutation carriers also owned other actionable or driver mutation in lung cancer, the most frequent one was TP53 (19%), followed by PIK3CA (10%), EGFR (8%), KRAS (8%), PTEN (3%) and ALK (3%). However, in colorectal cancer patients, we found that the BRAF functional mutation carriers owned the most frequent actionable mutation, one of which was TP53 (62%), followed by PIK3CA (35%) KRAS (31%), APC (27%), PTEN (19%) and BRCA2 (19%). We also found that one lung cancer patient has one BRAF fusion (BRAF-CTTNBP2).
Conclusions
BRAF gene mutations, especially BRAF non-V600, was extensively mutated in Chinese multiple cancer types. Our results revealed the potential targeted therapeutic strategies among non-V600 population with solid tumors should be considered in further study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yongjie Wang.
Funding
Has not received any funding.
Disclosure
L. Li. C. Liu: Financial Interests, Institutional, Full or part-time Employment: Yinfeng Gene Technology Co. Ltd. All other authors have declared no conflicts of interest.